Atossa Therapeutics Inc (ATOS): Net earnings per share growth forecast for next year

Optimized raw material supply chains eliminate logistics disruptions for Atossa Therapeutics (ATOS). The development of endoxifen to combat breast cancer provides portfolio diversification, while scientific rigor guarantees authority in oncology. The profit growth forecast for next year visualizes these successes, where 25.90 shows the value of this parameter, reflecting analyst expectations for the issuer's future earnings.

ATOS: Atossa Pharma Earnings growth forecast for next year 07/04/2022 - 11/11/2026

Metric breakdowns and analytics for atossatherapeutics.com (ATOS)

- share price and consensus valuation forecast:

Stock Price Atossa|ATOS - Average Forecast Price

- stock exchange capitalization data:

Market Value Atossa Therapeutics|ATOS - Business Value

- company book value details:

Book Value per Share Atossa Therapeutics|ATOS - Book Capitalization|Market Cap to Net Assets Ratio atossatherapeutics.com|ATOS - Aggregate Business Assets

- debt obligations and liquidity statistics:

Debt to Equity Atossa Therapeutics|ATOS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Atossa Therapeutics, Inc.|ATOS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Atossa Therapeutics|ATOS - Long-Term Debt Volume|Company Short-Term Debts Atossa Therapeutics|Quick Liquidity Indicator atossatherapeutics.com

- earnings and valuation multiples information:

ATOS - Final Profit|Future Profit Atossa Therapeutics|ATOS - Market Price to Net Income Ratio|Forward P/E Multiple Atossa Therapeutics|ATOS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Atossa Therapeutics|ATOS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Atossa Therapeutics|ATOS - Earnings per share for the trailing year|Quarterly EPS earnings growth atossatherapeutics.com|ATOS - Earnings growth in current year|Net earnings per share growth forecast for next year Atossa Therapeutics

Initial company analysis:ATOS, Atossa

Core merchandise of Atossa Therapeutics, Inc.

Developing innovative endocrine breast cancer therapies in partnership with clinics requires significant capital expenditures. The annual EPS forecast for Atossa Therapeutics (ATOS) reflects the consensus estimate of earnings per share growth rates, measuring the future monetization efficiency of these developments. By analyzing the price action on this chart, investors assess the company's ability to transform clinical success into actual cash flow. Growth in this indicator confirms market confidence in the commercial viability of the Atossa Therapeutics (ATOS) strategy.

Competitor analysis

MRUS (Merus Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Immutep Corp IMMP|Net earnings per share growth forecast for next year Anixa Biosciences, Inc. (ANIX)|contexttherapeutics.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year MRSN (Mersana Therapeutics, Inc.)|Earnings growth forecast for next year BriaCell Therapeutics Corp. BCTX|EPIX: Expected earnings per share growth for next year|QT Imaging, Inc. - Projected earnings per share increase next year